Dergiler / Haseki Tıp Bülteni / 2020 / Cilt: 58 - Sayı: 3

The Relationship of Osteoprotegerin with Cardiovascular Risk Factors in Women with and Without Polycystic Ovary Syndrome

Polikistik Over Sendromu ve Kontrol Grubu Hastalarda Osteoprotegerin ve Kardiyovasküler Risk Faktörleri Arasındaki İlişki

Sayfa
274–280
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Although OPG has been associated with endothelial dysfunction, atherosclerosis and coronary calcification in previous studies, currently not a useful marker for cardiovascular risk analysis in this patient population.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: In this study, we aimed to compare osteoprotegerin (OPG) levels in patients with and without polycystic ovary syndrome (PCOS) and to investigate the correlation between OPG levels and cardiovascular risk factors.
📊
Temel Bulgular & Veri:Methods: A total of 49 patients with PCOS and 31 age- and body mass index-matched healthy controls were included in the study.
💡
Sonuç & Katkı:Although OPG has been associated with endothelial dysfunction, atherosclerosis and coronary calcification in previous studies, currently not a useful marker for cardiovascular risk analysis in this patient population.
🔬Tür:Modelleme & Sayısal Simülasyon
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Aim: In this study, we aimed to compare osteoprotegerin (OPG) levels in patients with and without polycystic ovary syndrome (PCOS) and to investigate the correlation between OPG levels and cardiovascular risk factors. Methods: A total of 49 patients with PCOS and 31 age- and body mass index-matched healthy controls were included in the study. Blood samples were collected and hormonal and metabolic parameters and OPG levels were analyzed. The carotid intima-media thickness (CIMT) was measured for each patient and control through ultrasonography. Results: The low-density lipoprotein and total cholesterol levels were higher and the Homeostasis Model Assessment-Insulin Index (HOMA-IR) values were higher in patients with PCOS (p=0.002, p=0.037, and p=0.028, respectively). The OPG levels were 4.29 pmol/L and 4.07 pmol/L in the patient and control groups, respectively, indicating no significant difference between the groups. The CIMT was 0.57 in both groups. Conclusion: Our study results suggest that OPG levels appear to be similar in patients with PCOS and healthy controls. Although OPG has been associated with endothelial dysfunction, atherosclerosis and coronary calcification in previous studies, currently not a useful marker for cardiovascular risk analysis in this patient population.

Abstract

Amaç: Bu çalışmada amacımız, polikistik over sendromu tanısı olan ve olmayan hastalarda osteoprotegerin (OPG) düzeylerinin karşılaştırılması ve OPG düzeylerinin kardiyovasküler risk faktörleri ile ilişkisinin araştırılmasıdır. Yöntemler: Çalışmaya, aynı yaş ve vücut kitle indeksine sahip 49’u polikistik over sendromu ve 31’i kontrol grubunda olmak üzere toplam 80 hasta alındı. Hastalardan alınan kan örneklerinde, hormonal ve metabolik parametreler ile OPG düzeyleri değerlendirildi. Ultrasonografi ile her hastanın karotis arteri intima media kalınlığı ölçüldü. Bulgular: Biyokimyasal testler incelendiğinde, düşük dansiteli lipoprotein ve kolesterol düzeyleri ile homeostasis model assessment insulin indeks düzeyleri polikistik over grubunda daha yüksek bulundu (p=0,002, p=0,037, p=0,028). OPG düzeyi, polikistik over grubunda 4,29 pmol/L, kontrol grubunda ise 4,07 pmol/L saptandı. Her iki grupta karotis intima media kalınlığı 0,57 mm olarak ölçüldü. Sonuç: Çalışmada polikistik over grubu ile kontrol grubu arasında OPG düzeyleri ve karotis intima- media kalınlıkları açısından fark bulunmadı. Ayrıca OPG düzeyleri ile kardiyovasküler risk faktörleri arasında da bir bağlantı saptanmadı.

🔖

Bu Makaleye Atıf Yap

AYDIN, G. A., ÖZSOY, H. G. T. (2020). The Relationship of Osteoprotegerin with Cardiovascular Risk Factors in Women with and Without Polycystic Ovary Syndrome. Haseki Tıp Bülteni, Cilt: 58 - Sayı: 3, 274–280. https://ajindex.com/articles/162363

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-9
  2. Diamanti-Kandarakis E, Dunaif A.Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Reviews 2012;33:981-1030
  3. Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 2010;16:347-63
  4. Randeva HS, Tan BK, Weickert MO, et al. Cardiometabolic aspects of the polycystic ovary syndrome. Endocrine Reviews 2012;33:812-41
  5. Escobar-Morreale HF, Luque- Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome:a systematic review and metaanalysis. Fertility and Sterility 2011;95:1048-58
  6. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation 2016;133:e38-60
  7. Rochette L, Meloux A, Rigal E, Zeller M, Cottin Y, Vergely C. The Role of Osteoprotegerin and Its Ligands in Vascular Function.Int J Mol Sci 2019;6;20:705
  8. Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G. The osteoprotegerin/RANK/ RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006;4:801-11
  9. Schoppet M, Kavurma M, Hofbauer LC, Shanahan CM. Crystallizing nanoparticles derived fromvascular smooth muscle cells contain the calcification inhibitor osteoprotegerin.Biochemical and Biophysical Research Communications 2011;407:103-7
  10. Lawrie A, Waterman E, Southwood M, et al. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. American Journal of Pathology 2008;172:256-65
  11. Zannettino ACW, Holding CA, Diamond P, et al. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with vonWillebrand factor. Journal of Cellular Physiology 2005;204:714-23
  12. Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. Journal of theAmerican College of Cardiology 2010;55:2049-61
  13. Mangan SH, Van Campenhout A, Rush C, Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated wit